Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson’s disease: An open preliminary trial in Japan
Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson’s disease: An open preliminary trial in Japan
复制标题
帕金森病患者从麦角衍生的多巴胺激动剂一夜之间转换为普拉克索：日本的一项公开初步试验
DOI：
10.1016/j.jocn.2008.09.001
复制
发表时间：
2009
影响因子：
2
通讯作者：
M. Kawamura
中科院分区：
文献类型：
--
作者：
H. Ohno;M. Nakajima;S. Fujioka;K. Iwamoto;M. Kawamura
本研究的目的是评估帕金森病患者一夜之间从麦角衍生的多巴胺激动剂（如卡麦角林）切换到等效剂量的普拉克索的安全性和耐受性。由于卡麦角林的血浆半衰期长，转换后可能导致多巴胺能过量，因此夜间从卡麦角林切换到普拉克索的安全性尚未确定。纳入了22例连续的帕金森病患者，其中18例接受卡麦角林治疗。使用统一帕金森病评定量表（UPDRS）对患者进行评估，该量表在转换前以及治疗2、4、8和12周后给出。8例患者（36.4%）出现不良事件，其中2例退出研究。然而，一般情况下，UPDRS在治疗2周后得到显著改善，并持续改善至治疗12周。因此，我们的研究表明，如果患者依从性良好，一夜之间从麦角衍生的多巴胺激动剂（包括卡麦角林）切换到剂量相当的普拉克索是安全的。
The aim of this study was to evaluate the safety and tolerability of overnight switching from ergot-derived dopamine agonists such as cabergoline to equivalent doses of pramipexole in patients with Parkinson’s disease. The safety of overnight switching to pramipexole from cabergoline, which has a long plasma half-life and may cause dopaminergic excess after switchover, has not been established. Twenty-two consecutive patients with Parkinson’s disease were included, 18 of them on cabergoline treatment. Patients were assessed with the Unified Parkinson’s Disease Rating Scale (UPDRS) given just prior to switching as well as after 2, 4, 8, and 12 weeks of treatment. Eight patients (36.4%) experienced adverse events, of whom two were withdrawn from the study. Generally, however, significant improvement in the UPDRS was obtained after 2 weeks and improvement was maintained up to 12 weeks of treatment. Therefore, our study showed that overnight switching from ergot-derived dopamine agonists including cabergoline to dose-equivalent pramipexole was safe when associated with good patient compliance.
影响因子：
120.7
作者：
Holloway, R;Shoulson, I;Watts, A
通讯作者：
Watts, A